Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Endothelin System Clear all

Conditions: Cerebrovascular Trauma, Neurohormones, Cellular Apoptosis, Endothelin System
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Sacramento, California • Torrance, California • Miami, Florida + 5 more

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: BQ123, Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Airway Inflammation
Interventions: placebo, Montelukast; Other · Drug
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more

Conditions: Acute Ischemic Stroke, Cerebral Stroke
Interventions: Drug: Normal Saline, Sovateltide; Drug
Lead sponsor: Pharmazz, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more

Conditions: Portopulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 6
States / cities: La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 59
States / cities: Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more

Conditions: Diabetic Nephropathy
Interventions: SPP301; Drug
Lead sponsor: Speedel Pharma Ltd.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 2,364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 5 Days to 15 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more

Conditions: Prehypertension, Hypertension
Interventions: Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh; Drug · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 45 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Type 1 Diabetes
Interventions: Resveratrol, Placebo; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more

Conditions: Chronic Kidney Diseases
Interventions: Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan; Drug
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Observational Endothelin and Markers of Cellular Apoptosis In CSF Head Injury

The Role of Endothelin in the Supine Hypertension of Autonomic Failure

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

Nebivolol and the Endothelin (ET)-1 System

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria